Oxford Based Company Mirada Medical Brings Powerful PET/CT Oncology Software to UK Hospitals at BNMS Spring Meeting, Brighton 9th - 11th May 2011

OXFORD, UK and PHILADELPHIA, PA--(Marketwire - May 03, 2011) - Mirada Medical Limited, (“Mirada” or “the Company”) -- Patient-centric oncology workflows from UK company Mirada Medical Limited, are key to streamlining clinical practice in PET/CT and are being showcased by Mirada at the British Nuclear Medicine Society (BNMS) Spring Meeting, Brighton Conference Centre, 9th - 11th May 2011. Mirada’s innovative software products for cancer management are designed to enable users to be more efficient, and potentially more effective, in managing patient care from diagnosis through to treatment and monitoring of therapy response.

At the core of Mirada’s portfolio is the powerful XD3 software, providing clinical specialists with disease-specific oncology workflows for visualisation, quantification and tracking of patient scans from of any combination of vendor neutral CT, PET, MR and SPECT images over time. Coupled with Mirada’s registration engine, clinical assessment tools in XD3 include quantification such as PERCIST and RECIST, automated VOI propagation across timepoints, and connectivity with treatment planning systems. Users can quickly load an unlimited number of timepoints for comparison and XD3 can be customised for preferences of each specialist in a department, with fully configurable displays, layouts, quantification statistics and report templates.

With new PET-MR workflows in XD3, users can immediately realise the benefits of PET-MR through tri-modal fusion of an MRI scan with a PET/CT scan, or fusion of standalone PET to MRI. This software-based PET-MR provides powerful information during tumour assessment, staging, and delineation, with better visualisation of soft tissue abnormalities and tumours best localised using MR.

Founding Director, Professor Sir Michael Brady says “The combination of power and usability that the Mirada team achieve when developing medical imaging applications is quite unique in my experience. Their ability to take some of the most complex technologies, for example, image registration, and elegantly integrate these into accessible solutions for decision support in disease management sets the company aside from all the others in the field”.

Offering hospitals the power of flexibility and scalability within existing hospital IT infrastructure, XD3 works in conjunction with any PACS. Mirada’s deployment model for XD3 is specifically designed to enable hospitals to select the best clinical oncology software independent of purchasing decisions around PACS installations and upgrades. Native integrations of XD3 are also available through selected partners including Carestream, Vital Images, Sectra and McKesson. The vendor neutral nature of Mirada’s products also means XD3 can be used with all the major treatment planning companies for transfer of image data and contours.

To further support and streamline clinical workflow, Mirada has created a product, Caseaccess, which is complimentary to XD3 and allows remote referrers to review a case once read and reported.

Mirada’s portfolio of oncology products will be showcased at booth no. 9, at the BNMS Spring Meeting, Brighton Conference Centre, 9th - 11th May 2011.

About Mirada Medical

Mirada Medical is an internationally recognized brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada was originally spun out of the University of Oxford. The company’s technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.

Mirada’s products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada’s applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis.

Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada’s powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at tumor board.

Mirada demonstrate powerful PET/CT oncology software at BNMS meeting: http://hugin.info/143183/R/1511359/446709.pdf